Virios Therapeutics (NASDAQ:VIRI) Shares Down 14.6% – Time to Sell?

Virios Therapeutics, Inc. (NASDAQ:VIRI)’s stock price traded down 14.6% during trading on Monday . The stock traded as low as $10.10 and last traded at $11.40. 8,162,763 shares changed hands during mid-day trading, an increase of 678% from the average session volume of 1,049,645 shares. The stock had previously closed at $13.35.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price objective on Virios Therapeutics from $0.20 to $5.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th.

Virios Therapeutics Trading Down 13.4 %

The stock has a market capitalization of $290.03 million, a price-to-earnings ratio of -55.78 and a beta of 1.58. The company’s 50 day moving average is $3.44 and its 200 day moving average is $2.13.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.